Tracheal papillomatosis: what do we know so far?

Area of Science:

• Respiratory Medicine
• Oncology
• Virology

Background:

• Tracheal papillomatosis (TP) is a benign neoplastic condition affecting the bronchial epithelium, primarily involving the trachea.
• The etiology of TP is linked to infection with specific subtypes of the human papillomavirus (HPV), predominantly HPV-6 and HPV-11.

Observation:

• TP manifests in two distinct clinical forms: juvenile onset (JO) and adult onset (AO).
• Clinical presentation is often nonspecific, ranging from mild symptoms like cough to severe upper airway obstruction.

Findings:

• Treatment strategies for TP are individualized, considering papilloma location and patient age.
• Therapeutic options encompass conservative management, medical interventions, and surgical approaches for recurrent or progressive disease.

Implications:

• The development of the HPV vaccine represents a significant advancement with the potential to prevent and eradicate respiratory papillomatosis.
• Further research into HPV pathogenesis and vaccine efficacy is crucial for long-term management and prevention strategies.